Invigor 011
concept
4 mentions
1 recordings
first heard Oct 2024
last heard Oct 2024
↓4 vs the 12 months before
Study evaluating ctDNA‑guided adjuvant atezolizumab in bladder cancer
Trend
No mentions in the last 12M.Widen the range to see when Invigor 011 was said.
Moments
newest first · ▶ plays the momentDr. Bogdana SchmidtBackTable Urology · Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights wit... · 36:14 · Oct 2024
…And I think the prospective data at InVigor and Modern, like you mentioned, are going to give us that data and hopefully help us figure out how to interpret this so that we have less hesitation to get the data in the first place so that we sort of know what to do with it.…
Dr. Bogdana SchmidtBackTable Urology · Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights wit... · 34:10 · Oct 2024
…Correct. And that was 10%. So you said, you're right, for Tombola, it was 15%. Two patients, 3%, but in the Invigor, it was up to 10% of patients. But I kind of wonder if that has to do with the sensitivity of the assays. They were doing different assays in these studies.…
Dr. Andrea ApoloBackTable Urology · Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights wit... · 33:53 · Oct 2024
…In the early data presented from the InVigor 011, where they followed patients that were ctDNA negative, and they did see that some patients, although a really small percentage of patients that were ctDNA negative, did have progressive disease that was metastatic, that was not picked up.…
4 moments · sign in to read them all